External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home ASN 2024
Roche and Genentech at

ASN 2024

October 23 - October 27
San Diego, CA
asn.com
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Oct 24 / Roche and Genentech
Comparability of Two Anti-PLA2R ELISAs in Patients With Primary Membranous Nephropathy
This study compared the concordance between two anti-PLA2R assays used to measure anti-PLA2R antibody levels: the historical Brenchley ELISA and the new, widely available EuroImmun-ELISA, which is being used in the ongoing Phase III MAJESTY clinical trial (NCT04629248). The study also sought to determine the distribution of baseline serum anti-PLA2R levels to inform stratification thresholds for the MAJESTY trial.
Nephrology Membranous glomerulonephritis ASN-2024

Sign up or login to unlock the full suite of MEDICALLY features
Oct 24 / Roche and Genentech
MAJESTY: A Phase III, Randomized, Open-Label, Active Comparator-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy
This presentation outlines the study design of the Phase III MAJESTY clinical trial (NCT04629248), which is assessing the efficacy and safety of obinutuzumab versus tacrolimus in patients with primary membraneous nephropathy. Study recruitment and baseline characteristics are also presented.
Nephrology Membranous glomerulonephritis ASN-2024
05:00 PM
Duration 2hrs San Diego, CA
Comparability of Two Anti-PLA2R ELISAs in Patients With Primary Membranous Nephropathy
Barbour SJ, Clarke H, Berisha E, Arjomandi A, Chen D, Riboulet W, Boston H, Prot S, Cattran DC, Place DE
Nephrology | Membranous glomerulonephritis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:30 PM
Duration 10mins Room 1 (Convention Center)
MAJESTY: A Phase III, Randomized, Open-Label, Active Comparator-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy
Fervenza F, Gesualdo L, Kirsztajn GM, Hou FF, Appel G, Prot S, Berisha E, Khatri L, Parsons T, Spinks E, Boston H, Riboulet W, Han X, Chen DC, Bomback A
Nephrology | Membranous glomerulonephritis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.